ISRCTN44536106已完成不适用
GEO 001: What is the dose-response curve between allopurinol and its effects on endothelial function in heart failure patients?
niversity of Dundee (UK)0 个研究点目标入组 30 人开始时间: 2006年1月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Three-month period free of hospitalisations prior to screening
- •2. Ability to give written informed consent to participate in the study
- •3. Diagnosis of mild to moderate chronic heart failure
排除标准
- •1. History of drug sensitivity or allergy to allopurinol or vitamin C
- •2. Current treatment with allopurinol , theophylline or cytotoxic drugs (including azothiaprine or mercaptopurine)
- •3. History of acute gout
- •4. Evidence of significant disease that could impair absorption, metabolism or excretion of orally administered medication i.e.
- •a. Renal disease (serum creatinine >160 umol/l)
- •b. Clinically significant hepatic disease (either by lab work, i.e. alanine aminotranferease (ALT) and aspartate aminotransferase (AST) (ALT/AST > 3 times upper limit of normal, or by clinical assessment)
- •5. Any condition with sufficient severity to impair co-operation in the study
- •6. History of chronic alcoholism / intravenous drug abuse
- •7. Use of another investigational drug within three months of entry into the study or within five half-lives of the investigational drug (the longer time period applying)
- •8. Pregnancy, breast feeding or being of childbearing age and not taking oral contraceptives
研究者
相似试验
进行中（未招募）
不适用
An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence.A 12-week, randomised, double-blind, placebo-controlled, multicentre study, parallel-group, Phase III clinical study with a 12 months safety follow-up period.rge Urinary IncontinenceEUCTR2004-001119-69-ESaboratorios Dr. Esteve, SA450
进行中（未招募）
1 期
An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence.A 12-week, randomised, double-blind, placebo-controlled, multicentre study, parallel-group, Phase III clinical study with a 12 months safety follow-up period.rge Urinary IncontinenceEUCTR2004-001119-69-CZaboratorios Dr. Esteve, SA450
已完成
不适用
Optimising allopurinol therapy in the treatment of gout.GoutInflammatory and Immune System - Other inflammatory or immune system disordersMusculoskeletal - Other muscular and skeletal disordersACTRN12611000743965Richard Day30
进行中（未招募）
1 期
Investigation of dose response relationships when using low dose naltrexone (LDN) for the treatment of fibromyalgiaFibromyalgiaMedDRA version: 20.0Level: LLTClassification code 10016631Term: Fibromyalgia syndromeSystem Organ Class: 100000004859EUCTR2016-002081-31-DKAnæstesiologisk-intensiv afd V, Odense Universitets Hospital38
已完成
不适用
Observational study for radiation biodosimetry.CTRI/2019/07/020109Manipal School of Life Sciences5